Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0230)
Name
Wogonin
Synonyms
Wogonin; 632-85-9; 5,7-Dihydroxy-8-methoxyflavone; Vogonin; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-methoxy-2-phenyl-; Norwogonin 8-methyl ether; 5,7-dihydroxy-8-methoxy-2-phenyl-4H-chromen-4-one; 5,7-dihydroxy-8-methoxy-2-phenylchromen-4-one; FLAVONE, 5,7-DIHYDROXY-8-METHOXY-; POK93PO28W; CHEMBL16171; CHEBI:10043; 5,7-Dihydroxy-8-methoxy-2-phenyl-chromen-4-one; UNII-POK93PO28W; BRN 0287152; wagonin; Wogonin hydrate; Wogonin,(S); 5,7-dihydroxy-8-methoxy-2-phenyl-4H-1-benzopyran-4-one; ST077088; WOGONIN [INCI]; Wogonin, S. baicalensis; MLS002473006; SCHEMBL139083; DTXSID70212557; HMS2270G08; AMY25744; HY-N0400; BDBM50140257; HB4126; LMPK12111330; MFCD00017736; NSC717845; s4743; AKOS015917860; CCG-208499; CS-3959; NSC-717845; NCGC00247464-01; AC-20338; AC-32550; AS-70103; NCI60_040649; SMR001397111; FT-0603499; W0010; Q409606; SR-05000002216; Q-100730; SR-05000002216-2; 5,7-Dihydroxy-8-methoxy-2-phenyl-chromen-4-one(Wogonin); 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-methoxy-2-phenyl-; Flavone, 5,7-dihydroxy-8-methoxy- (7CI,8CI); Wogonin (6CI); 5,7-Dihydroxy-8-methoxy-2-phenyl-4H-1-benzopyran-4-one; 5,7-Dihydroxy-8-methoxyflavone

    Click to Show/Hide
Structure
Formula
C16H12O5
IUPAC Name
5,7-dihydroxy-8-methoxy-2-phenylchromen-4-one
Canonical SMILES
COC1=C(C=C(C2=C1OC(=CC2=O)C3=CC=CC=C3)O)O
InChI
InChI=1S/C16H12O5/c1-20-15-12(19)7-10(17)14-11(18)8-13(21-16(14)15)9-5-3-2-4-6-9/h2-8,17,19H,1H3
InChIKey
XLTFNNCXVBYBSX-UHFFFAOYSA-N
PubChem CID
5281703
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Pancreatic cancer ICD-11: 2C10
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model PANC-1 cells Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
AsPC-1 cells Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0152
HPDE6-C7 cells Normal Homo sapiens CVCL_0P38
In Vivo Model
Female BALB/c nude mice (5 weeks old) were procured from Hangzhou Ziyuan Laboratory Animal Technology Co., Ltd (Zhejiang, China) and given 5 days to acclimate to their surroundings. PANC-1 cells (1 x 107) in 100 uL PBS at the logarithmic growth phase were administered to mice subcutaneously in the left flank. The mice were treated with indicated treatments after nearly 10 days when the tumour size was approximately 1,000 mm3. In the control group, mice (n = 5) received intraperitoneal injections of the vehicle. In the treatment group, the mice (n = 5) were administered 50 uL of 60 mg/kg body weight of wogonin once a day for 12 days. A slide calliper size was used to measure the tumour size. The equation for calculating tumour volume is as follows: tumour volume = AB2/2, wherein A is the length, and B is the width of the tumour. The mice were sacrificed the next day after the treatment procedure was complete by cervical dislocation. The tumour tissues were harvested and snap-frozen using liquid nitrogen for subsequent analyses.

    Click to Show/Hide
Response regulation Wogonin could significantly reduces pancreatic cancer cell proliferation and induce ferroptosisviathe Nrf2/GPX4 axis. Therefore, wogonin could be potentially used for treating patients with pancreatic cancer.
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Pancreatic cancer ICD-11: 2C10
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model PANC-1 cells Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
AsPC-1 cells Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0152
HPDE6-C7 cells Normal Homo sapiens CVCL_0P38
In Vivo Model
Female BALB/c nude mice (5 weeks old) were procured from Hangzhou Ziyuan Laboratory Animal Technology Co., Ltd (Zhejiang, China) and given 5 days to acclimate to their surroundings. PANC-1 cells (1 x 107) in 100 uL PBS at the logarithmic growth phase were administered to mice subcutaneously in the left flank. The mice were treated with indicated treatments after nearly 10 days when the tumour size was approximately 1,000 mm3. In the control group, mice (n = 5) received intraperitoneal injections of the vehicle. In the treatment group, the mice (n = 5) were administered 50 uL of 60 mg/kg body weight of wogonin once a day for 12 days. A slide calliper size was used to measure the tumour size. The equation for calculating tumour volume is as follows: tumour volume = AB2/2, wherein A is the length, and B is the width of the tumour. The mice were sacrificed the next day after the treatment procedure was complete by cervical dislocation. The tumour tissues were harvested and snap-frozen using liquid nitrogen for subsequent analyses.

    Click to Show/Hide
Response regulation Wogonin could significantly reduces pancreatic cancer cell proliferation and induce ferroptosisviathe Nrf2/GPX4 axis. Therefore, wogonin could be potentially used for treating patients with pancreatic cancer.
References
Ref 1 Wogonin induces ferroptosis in pancreatic cancer cells by inhibiting the Nrf2/GPX4 axis. Front Pharmacol. 2023 Feb 22;14:1129662. doi: 10.3389/fphar.2023.1129662. eCollection 2023.